Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib combined with R-ICE for relapsed or refractory diffuse large B-cell lymphoma
ChiCTR1900028655Phase 2Not yet recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib, rituximab, ifosfamide, carboplatin and etoposide in diffuse large B-cell lymphoma (DLBCL), sponsored by Shanghai Ninth People's Hospital. Primary endpoints: Tumor progression and remission by imaging, Peripheral blood and 1 more. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
anlotinibrituximabifosfamidecarboplatinetoposide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR1900028655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900028655.